MedTrace Logo

A Study of Hospital-at-Home for People Receiving Tarlatamab

NCT06957314 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).

Conditions

  • Small-cell Lung Cancer
  • Small Cell Lung Carcinoma

Interventions

OTHER

Hospital-at-Home/HAH

After discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence

Sponsors & Collaborators

Principal Investigators

  • Robert Daly, MD, MBA · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-23
Primary Completion
2028-04-23
Completion
2028-04-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06957314 on ClinicalTrials.gov